A Translational Approach to Identify Drugs with Specific Activity Against EZH2 Mutant High Risk T-ALLs and ETP ALLs that Overexpress the JDP2 bZIP Transcription Factor |
Dana-Farber Cancer Institute / Shuning He, PhD |
Young Investigator Grants |
2015 |
Massachusetts |
Role of LMO1 in Neuroblastoma Initiation and Maintenance: Analysis in the Zebrafish model of Childhood Neuroblastoma |
Dana-Farber Cancer Institute / Thomas Look, M.D. |
Innovation Grants |
2014 |
Massachusetts |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
Targeted Hyperactivation of PI3K/AKT in B-cell malignancies |
Dana-Farber Cancer Institute / Vishal Khairnar, PhD |
Young Investigator Grants |
2019 |
Massachusetts |
Modeling the Multi-hit Pathogenesis of t(12;21) Associated Pediatric ALL by CRISPR/Cas-mediated Genome Engineering |
Massachusetts General Hospital / Hanno Hock, M.D., Ph.D. |
Innovation Grants |
2014 |
Massachusetts |
Dissecting the Contribution and Inheritance of Germline DNA Damage Repair Gene Mutations in Neuroblastoma |
Dana-Farber Cancer Institute / Riaz Gillani, MD |
Young Investigator Grants |
2021 |
Massachusetts |
A mouse model of Wilms' Tumor
|
Massachusetts General Hospital / Nabeel Bardeesy, PhD |
Young Investigator Grants |
2008 |
Massachusetts |
Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma |
Massachusetts General Hospital / Rakesh Jain, PhD |
Reach Grants |
2013 |
Massachusetts |
Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML |
Boston Children’s Hospital / Alan Cantor, MD, PhD |
RARE Grant Program (Research Accelerating RUNX1 Exploration) |
2016 |
Massachusetts |
Investigating the role of lin-28 in germ cell tumorigenesis
|
Boston Children’s Hospital / George Daley |
Innovation Grants |
2009 |
Massachusetts |